Mesoblast (DB:LWB1) - Cotización, noticias y análisis

Resumen de acción LWB1

Mesoblast Limited se dedica al desarrollo de productos de medicina regenerativa en Australia, Estados Unidos, Singapur y Suiza.

Acerca de la empresa

LWB1 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	5/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Recompensas

Cotiza un 98.8% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 57.85%

Los beneficios han crecido 0.4% al año en los últimos 5 años

Análisis de riesgos

Acciones altamente ilíquidas

Los accionistas han sido diluidos sustancialmente en el último año

Competidores de Mesoblast Limited

Formycon

XTRA:FYB

€682.6m

Biotest

XTRA:BIO3

€1.4b

MorphoSys

XTRA:MOR

€2.5b

Heidelberg Pharma

XTRA:HPHA

€139.8m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Mesoblast
Historical stock prices
Current Share Price	AU$1.87
52 Week High	AU$8.68
52 Week Low	AU$1.86
Beta	2.59
1 Month Change	0%
3 Month Change	0.54%
1 Year Change	-69.24%
3 Year Change	-87.10%
5 Year Change	-80.02%
Change since IPO	-82.45%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	LWB1	DE Biotechs	Mercado DE
7D	0%	-5.9%	-1.7%
1Y	-69.2%	-21.4%	-0.2%

Rentabilidad vs. Industria: LWBA obtuvo unos resultados inferiores a los del sector German Biotechs , que el año pasado arrojó un rendimiento del -23.1%.

Rentabilidad vs. Mercado: LWBA obtuvo unos resultados inferiores a los del mercado German, que fue del 5.9% el año pasado.

Volatilidad de los precios

Is LWB1's price volatile compared to industry and market?
LWB1 volatility
LWB1 Average Weekly Movement	n/a
Biotechs Industry Average Movement	4.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.0%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: LWB1 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de LWB1 en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2004	83	Silviu Itescu	www.mesoblast.com

Mesoblast Limited se dedica al desarrollo de productos de medicina regenerativa en Australia, Estados Unidos, Singapur y Suiza. La empresa ofrece productos en las áreas cardiovascular, de trastornos ortopédicos de la columna vertebral, oncología, hematología y enfermedades inmunomediadas e inflamatorias. Su plataforma tecnológica patentada de medicina regenerativa se basa en células especializadas conocidas como células de linaje mesenquimal.

Resumen de fundamentos de Mesoblast Limited

¿Cómo se comparan los beneficios e ingresos de Mesoblast con su capitalización de mercado?
Estadísticas fundamentales de LWB1
Capitalización bursátil	€598.87m
Beneficios(TTM)	-€67.42m
Ingresos (TTM)	€6.89m

86.9x

Ratio precio-ventas (PS)

-8.9x

Ratio precio-beneficio (PE)

¿Está LWB1 sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de LWB1
Ingresos	US$7.47m
Coste de los ingresos	US$48.13m
Beneficio bruto	-US$40.66m
Otros gastos	US$32.40m
Beneficios	-US$73.06m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.064
Margen bruto	-544.50%
Margen de beneficio neto	-978.41%
Ratio deuda/patrimonio	22.8%

¿Cómo se ha desempeñado LWB1 a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción LWB1

Recompensas

Análisis de riesgos

Competidores de Mesoblast Limited

XTRA:FYB

€682.6m

XTRA:BIO3

€1.4b

XTRA:MOR

€2.5b

XTRA:HPHA

€139.8m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 0.93 million.

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 97.041224 million.

Mesoblast Limited Announces United States Food & Drug Administration Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with A Left Ventricular Assist Device

United States Food & Drug Administration Grants Mesoblast Rare Pediatric Disease Designation for Revascor®? (Rexlemestrocel-L) in Children with Congenital Heart Disease

Mesoblast Limited, Annual General Meeting, Nov 28, 2023

Recent updates

United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 0.93 million.

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 97.041224 million.

Mesoblast Limited Announces United States Food & Drug Administration Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with A Left Ventricular Assist Device

United States Food & Drug Administration Grants Mesoblast Rare Pediatric Disease Designation for Revascor®? (Rexlemestrocel-L) in Children with Congenital Heart Disease

Mesoblast Limited, Annual General Meeting, Nov 28, 2023

Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee

Mesoblast Limited Provides an Update on the Path to Approval for Its Lead-Product Candidate Remestemcel-L in the Treatment of Pediatric and Adult Steroid-Refractory Acute Graft Versus Host Disease

Mesoblast Limited Receives Complete Response from U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children

Mesoblast Limited Appoints Dr. Philip R. Krause, Member of the Board of Directors, to Formal Strategic Advisory Role

Remestemcel-L Clinical and Potency Studies Presented At Premier Meeting of Transplantation Research and Therapy

Mesoblast Limited Announces FDA Grants Regenerative Medicine Advanced Therapy Designation for Rexlemestrocel-L in Chronic Low Back Pain

Mesoblast Limited Resubmits Biologic License Application to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)

Mesoblast Limited Announces Top-Line Long-Term Survival Results for Remestemcel-L from its Pivotal Phase 3 Trial (GVHD-001) in Children with Steroid-Refractory Acute Graft-Versus-Host Disease

Mesoblast Limited, Annual General Meeting, Nov 23, 2022

Mesoblast Limited Submits New Information to FDA File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD

Mesoblast Limited Announces Board Changes

Mesoblast Limited Announces Single Intervention with Rexlemestrocel-L Improves Left Ventricular Ejection Fraction At 12 Months, Preceding Long-Term Reduction in Major Adverse Cardiovascular Events

Mesoblast Limited Provides Litigation Update

Mesoblast Limited Provides Update on Survival Outcomes in Covid-19 ARDS Patients Treated with Remestemcel-L

Mesoblast Limited Announces Class Action Proceeding in the Federal Court of Australia

Mesoblast Limited Announces Executive Changes

Donal O'Dwyer Retires from the Board of Mesoblast Limited

Mesoblast Limited Announces Positive Results from an Interim Analysis of the First Patient Cohort in the Randomized, Controlled Study of Remestemcel-L by Direct Endoscopic Delivery to Areas of Inflammation in Patients with Medically Refractory Ulcerative Colitis or Crohn's Colitis

Mesoblast Limited Appoints Eric Rose as Chief Medical Officer

Mesoblast Limited Announces 36-Month Results of Phase 3 Trial in Chronic Low Back Pain

Mesoblast Limited Receives Feedback from the US Food & Drug Administration’S Office of Tissues and Advanced Therapies on the Phase 3 Program of Rexlemestrocel-L

Mesoblast Limited announced that it expects to receive $90 million in funding from Oaktree Capital Management, L.P.

Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference

Mesoblast Limited Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease

Mesoblast Limited Improves Outcomes in Inflammatory Lung Disease with Remestemcel-L Published in Respiratory Research Journal

Mesoblast Limited Announces the 60 Day Results from the Randomized Controlled Trial of remestemcel-L in 222 Ventilator-Dependent COVID-19 Patients with Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) Which Had Been Halted After the Third Interim Analysis

Mesoblast Limited announced that it expects to receive AUD 138.251367 million in funding

Mesoblast Limited Announces Positive Outcomes of First Children Treated with Remestemcel-L for Multisystem Inflammatory Syndrome (MIS-C) and Heart Failure Post-Covid-19 Published in Pediatrics

Mesoblast Limited Announces Results from the Phase 3 Randomized Controlled Trial of Its Allogeneic Mesenchymal Precursor Cell Therapy

Mesoblast Limited Presents Heart Failure Phase 3 Trial Results At Investor Healthcare Conference

Mesoblast Limited Announces Additional Results from the Landmark Dream-Hf Randomized Controlled Phase 3 Trial in 537 Treated Patients with Chronic Heart Failure with Reduced Left Ventricular Ejection Fraction (HFrEF) Who Received Rexlemestrocel-L (REVASCOR) or Control Sham

Mesoblast Limited Announces Update on Covid-19 ARDS Trial

Mesoblast Provides Topline Results From Phase 3 Trial of Rexlemestrocel-L for Advanced Chronic Heart Failure

Mesoblast Limited Announces United States Food and Drug Administration Granted Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to Covid-19 Infection

Mesoblast Limited Announces FDA Grants Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to COVID-19

Mesoblast Limited announced that it expects to receive $25 million in funding from Novartis AG

Mesoblast Limited Enters into an Exclusive Worldwide License and Collaboration Agreement with Novartis for the Development, Manufacture and Commercialization of Remestemcel-L

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been File Against Precigen, Royal Caribbean, Mesoblast and Loop Industries

The Law Offices of Frank R. Cruz Announces Class Action Lawsuit Against Mesoblast Limited

Rosen Law Firm Reminds Mesoblast Limited Investors of Important Deadline

Mesoblast Limited Announces Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Mesoblast Limited

Mesoblast Limited Announces US Food and Drug Administration Issues Complete Response Letter to its Biologics License Application

Mesoblast Limited Announces Updates on RYONCIL

Mesoblast Limited Receives Complete Response Letter from US Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children

Mesoblast Limited Auditor Raises 'Going Concern' Doubt

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 0.33959 million.

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Mesoblast Limited

86.9x

-8.9x